Interestingly, CARMN was highly abundant in SMC2 cells in the control group, and its expression was downregulated in parallel with the reduction in SMC2 expression in the AAA group (Fig. 1M, N), suggesting that CARMN may participate in regulating HVSMC contractile activity during the progression of AAA. The gene discussed is CARMN; the disease is triple-A syndrome.